bioAffinity Technologies Secures $4M in At-the-Market Stock Offering

  • bioAffinity Technologies raised ~$4M via registered direct offering and concurrent private placement at $6.122 per share.
  • Offering includes pre-funded warrants and warrants to purchase up to 980,072 shares, exercisable post-stockholder approval.
  • Proceeds earmarked for working capital and scaling CyPath® Lung, its noninvasive lung cancer detection test.
  • Closing expected October 9, 2026, subject to customary conditions.

The $4M raise underscores bioAffinity’s push to scale CyPath® Lung amid growing demand for early-stage lung cancer diagnostics. The at-the-market offering reflects strategic flexibility in capital markets, though execution hinges on differentiating its noninvasive test in a crowded field. The deal size, while modest, signals investor confidence in the company’s CLIA-compliant pathway to market.

Execution Risk
Whether bioAffinity can deploy proceeds effectively to drive CyPath® Lung adoption amid competitive diagnostics landscape.
Market Dynamics
How the $4M infusion positions bioAffinity against larger players in noninvasive cancer detection.
Regulatory Headwinds
The pace at which CLIA oversight may impact CyPath® Lung’s commercialization strategy.